Project Grant R56AG083570
- This Project Grant award for $380,060 from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) supports research by the Arizona Veterans Research And Education Foundation, a non-profit organization, to evaluate anti-Medin immunotherapy for addressing vascular aging and related dementias. The project aims to develop and test the efficacy of an anti-Medin vaccine (Aim 1) as well as anti-Medin monoclonal antibodies (Aim 2) in preventing or attenuating...
- Federal Grant Award Summary Vanderbilt University Medical Center received a $1.47 million Project Grant from the National Institute on Aging (Aging Research program, CFDA 93.866) awarded January 1, 2026, with a completion date of December 31, 2030. The grant supports research to probe mechanistic links between endothelial aging and dementia by developing a novel human induced pluripotent stem cell-endothelial cell (hiPSC-EC) model of aging. The research will leverage cells differentiated from...
- This Project Grant award of $5,949,022, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to identify novel therapeutic targets for treating cerebral amyloid angiopathy (CAA) and vascular contributions to cognitive impairment and dementia (VCID). The research, led by the Jackson Laboratory with sub-awards to Emory University, Rush...
- The National Institute on Aging (NIA) awarded a $2,244,471 Project Grant under CFDA 93.866 (Aging Research) to Oregon Health & Science University (OHSU) to develop a first-in-class, CNS-penetrant small molecule agonist for G protein-coupled receptor 39 (GPR39) as a potential treatment for vascular cognitive impairment and dementia (VCID). The 3-year project from September 2023 to August 2026 will use in vitro and in vivo assays to identify lead compounds, determine their safety and...
- Federal Project Grant Summary The National Institute on Aging (NIA) awarded New York University School of Medicine a $3.104 million Project Grant on September 15, 2025, under the Aging Research program (CFDA 93.866) to investigate the relationship between peripheral immune dysfunction and vascular contributions to cognitive decline and dementia. The research integrates blood biomarker analysis—specifically measuring platelet aggregation, neutrophil activity, and proteomic data—with advanced...
- This Project Grant awarded by the National Institute on Aging (CFDA 93.866 - Aging Research) will provide $10,847,672 to the J. David Gladstone Institutes, a non-profit biomedical research organization, to investigate the vascular-immune mechanisms underlying cerebral amyloid angiopathy (CAA) and Alzheimer's disease pathology. The research aims to elucidate the key microglial mechanisms regulating the formation of vascular CAA versus parenchymal amyloid-beta plaques, define single-cell and...
- This $847,000 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research by The Medical College of Wisconsin, Inc. (MCW) to determine whether extracellular vesicle-enclosed Y5-RNA mediates the age-dependent impairment of angiogenesis (the formation of new blood vessels). The research aims to examine if decreases in Y5-RNA in endothelial cell-derived extracellular vesicles contribute to endothelial cell senescence and impaired angiogenesis in aged...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $431,750 aims to isolate and characterize peptide ligands targeting vascular endothelial cells (VECs) in young versus aged mice in vivo and senescent versus non-senescent murine VECs in vitro. The primary objectives are to enhance the understanding of molecular mechanisms and age-related pathologies associated with vascular dysfunction during aging. The project seeks to...
- This Project Grant award of $437,875 from the National Institute on Aging's Aging Research program (CFDA 93.866) will fund a 2-year research project at the University of California, San Diego to quantify neurovascular protein lifetimes in the central nervous system under healthy, aging, and Alzheimer's disease conditions. The key objectives are to generate a comprehensive atlas of neurovascular protein lifetimes and identify changes associated with aging and Alzheimer's disease. The project will...
- The Vanderbilt Alzheimer's Disease Research Center (VADRC), funded by the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866), received a $10.1 million Project Grant awarded June 1, 2025, with a completion date of March 31, 2030. The center aims to establish a world-class interdisciplinary research facility in Nashville, Tennessee, focusing on understanding the intersection between vascular risk factors and Alzheimer's disease and related dementias (ADRD), with...
UNDERSTANDING VASCULAR AGING-RELATED DEMENTIA THROUGH MEDIN SIGNALING - ABSTRACT AGE IS THE MOST IMPORTANT RISK FACTOR FOR CARDIO-CEREBROVASCULAR DISEASES AND DEMENTIA DISORDERS. EPIDEMIOLOGIC, PRECLINICAL AND CLINICAL DATA SHOW THAT VASCULAR DISEASE IS STRONGLY ASSOCIATED WITH DEMENTIA DISORDERS, INCLUDING ALZHEIMER'S DISEASE (AD) AND AD-RELATED DISORDERS SUCH AS VASCULAR DEMENTIA (VAD). THE MECHANISTIC LINKS AMONG VASCULAR DISEASE, AGING AND DEMENTIA REMAIN POORLY UNDERSTOOD. THERE IS GROWING EVIDENCE THAT MEDIN, A 50-AMINO ACID PEPTIDE THAT FORMS ONE OF THE MOST COMMON YET LEAST STUDIED HUMAN AMYLOIDOSES, IS AN IMPORTANT DRIVER OF VASCULAR AGING PATHOLOGIES. MEDIN ACCUMULATES IN THE VASCULATURE WITH AGING AND IS IMPLICATED IN AD, VAD AND AORTIC DISEASE. LITTLE IS KNOWN AS TO THE MECHANISMS BY WHICH MEDIN INDUCES CELL AND TISSUE INJURY, AND NO ANIMAL MODEL OF MEDIN PATHOLOGY CURRENTLY EXISTS. WE SHOWED THAT MEDIN IMPAIRED ENDOTHELIAL FUNCTION AND CELL VIABILITY AND INDUCED PRO-INFLAMMATORY ACTIVATION, IN PART THROUGH RECEPTOR FOR ADVANCED GLYCATION ENDPRODUCTS (RAGE). OUR GOALS ARE TO DISCOVER BIOLOGICAL PATHWAYS OF MEDIN TOXICITY USING NOVEL GENOME-WIDE CRISPR/CAS9 KNOCKOUT GENETIC SCREENING, TEST F(BA)S PEPTIDE AND RAGE KNOCKOUT TO REVERSE MEDIN TOXICITY AND TEST THE IN VIVO ROLE OF MEDIN IN VASCULO-NEUROPATHOLOGY BY CREATING A MOUSE MODEL WITH ENDOTHELIAL OVEREXPRESSION OF MEDIN. IN AIM 1, WE WILL PROBE TOXIC SIGNALING MECHANISMS USING A SYNTHETIC LETHALITY-BASED GENOME-WIDE CRISPR/CAS9 SCREENING IN ENDOTHELIAL CELLS. THIS WILL GENERATE A LIST OF CANDIDATE GENES/PATHWAYS THAT FACILITATE OR PROTECT AGAINST MEDIN TOXICITY AND COULD BE POTENTIAL DRUG TARGETS. IN AIM 2, WE WILL TEST IF PEPTIDE F(BA)S CAN REVERSE MEDIN TOXICITY IN CULTURED ENDOTHELIAL CELLS AND EX VIVO IN ISOLATED HUMAN DONOR HUMAN CEREBRAL ARTERIES. IN AIM 3, WE WILL TEST IN VIVO THE ROLE OF MEDIN IN AGING-INDUCED VASCULAR AND COGNITIVE DYSFUNCTION AND ASSESS WHETHER RAGE KNOCKOUT WILL BE PROTECTIVE. IN AN EXPLORATORY SUBAIM, WE WILL CREATE A TRANSGENIC MOUSE MODEL OF ENDOTHELIUM-SPECIFIC MEDIN OVEREXPRESSION. ONCE SUCCESSFULLY IMPLEMENTED, THE PROPOSAL WILL SHED LIGHT ON THE MECHANISMS UNDERLYING MEDIN VASCULO-NEUROPATHOLOGY AND CREATE A VALUABLE AND NOVEL PRECLINICAL ANIMAL MODEL OF VASCULAR AGING THAT CAN BE USED TO IDENTIFY AND TEST NEW DRUG TARGETS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | ($1k) | 3/17/26 | ||
| Not listed | $471.6k | 8/25/23 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
UNDERSTANDINGVASCULARAGINGS | University Of Liverpool | Project Grant R56AG083570 | $85.7k | 10/1/25 | |
UNDERSTANDINGVASCULARAGINGS | Dignity Health | Project Grant R56AG083570 | $39.7k | 10/1/25 | |
UNDERSTANDINGVASCULARAGINGS | Banner Health | Project Grant R56AG083570 | $14.5k | 10/1/25 |